Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
Ability Biologics Closes $18 Million Seed Funding Extension for Immunomodulators
Details : The financing aims to support AI in therapeutic discovery, focusing its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : Antibody-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Charles River Laboratories, Inc
Deal Size : $18.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?